20/20 Biolabs, Inc. plans to list on the Nasdaq Capital Market under the symbol AIDX. It filed a Form S-1 registration statement for an initial public offering on December 12, 2025. As of November 6, 2026, its registration is amended and on file (Form S-1, April 6, 2026).
Sell to companies like 20/20 Biolabs, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
20/20 Biolabs, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-12-12. It has amended it 2 times. As of its latest filing, on 2026-04-06, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
Also on the record for 20/20 Biolabs, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 10, 2026 | Stake report, Schedule 13D, by Jonathan M Cohen | 16.8% of the class | 5%+ stakes | Source |
| March 10, 2026 | Stake report, Schedule 13G, by Full Succeed International Limited | 6.3% of the class | 5%+ stakes | Source |
| February 25, 2026 | Stake report, Schedule 13G, by Streeterville Capital LLC | 9.9% of the class | 5%+ stakes | Source |
| December 12, 2025 | Crowdfunding filing, Form C/A | $10K target | Crowdfunding | Source |
| November 26, 2025 | Crowdfunding filing, Form C/A | $10K target | Crowdfunding | Source |
| November 4, 2025 | Crowdfunding filing, Form C/A | $10K target | Crowdfunding | Source |
| October 30, 2025 | Crowdfunding filing, Form C | $10K target | Crowdfunding | Source |
| August 13, 2025 | Crowdfunding filing, Form C-U | $10K target | Crowdfunding | Source |
| August 6, 2025 | Crowdfunding filing, Form C/A | $10K target | Crowdfunding | Source |
| July 8, 2025 | Crowdfunding filing, Form C/A | $10K target | Crowdfunding | Source |
| July 8, 2025 | Crowdfunding filing, Form C/A | $10K target | Crowdfunding | Source |
| May 20, 2025 | Crowdfunding filing, Form C | $10K target | Crowdfunding | Source |
Check before you invest in 20/20 Biolabs, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on 20/20 Biolabs, Inc. and the records around it.
20/20 Biolabs, Inc. elsewhere on the record
- 5%+ stake filings Mar 2026
- Crowdfunding filing Dec 2025
- Who owns it
Companies that share a holder
- Streeterville Capital LLC also filed stake reports on 29 other companies: Professional Diversity Network, Inc. (Oct 2026), Solowin Holdings, Ltd. (Oct 2026), Vivos Therapeutics, Inc. (Sep 2026)
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q2 2026, newest first.
- Tenon Medical, Inc. (Jun 2026)
- Exyn Technologies, Inc. (Jun 2026)
- bioAffinity Technologies, Inc. (Jun 2026)
Watch 20/20 Biolabs, Inc.
Get an email when 20/20 Biolabs, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on 20/20 Biolabs, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 20/20 Biolabs, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 20/20 Biolabs, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
What the filings say
Listing
Our common stock is listed on The Nasdaq Capital Market under the symbol “AIDX.” On April 2, 2026, the last reported sale price of our common stock on The Nasdaq Capital Market was $1.83.From the S-1 filed 2026-04-06
Use of proceeds
We currently expect to use the net proceeds that we receive from the exercise of the warrant for working capital and other general corporate purposes.From the S-1 filed 2026-04-06
Revenue
in the case of an issuer whose public float as calculated under paragraph (1) or (2) of this definition was zero or whose public float was less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available.From the S-1 filed 2026-04-06
Net loss or income
As a result of the cumulative effect of the factors described above, we generated a net loss of $3,738,821 for the year ended December 31, 2025, as compared to $5,551,667 for the year ended December 31, 2024, a decrease of $1,812,846, or 32.65%.From the S-1 filed 2026-04-06
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-12-12 | Registration statement filed | S-1 |
| 2026-01-21 | Registration statement amended | S-1/A |
| 2026-01-26 | Registration statement amended | S-1/A |
| 2026-04-06 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for 20/20 Biolabs, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.